Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gilead SciencesXTER:GIS -0.66%82 EV-to-FCF is 17.79 as of Jul. 14, 2026, which is 46% above its 10-year median of 12.15. GuruFocus rates XTER:GIS with a GF Score™ of 82/100 and a GF Value™ of €83.02 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 562 Drug Manufacturers companies, Gilead Sciences ranks better than 59.61% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gilead Sciences's Enterprise Value is €155,944 Mil.
Gilead Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €8,765 Mil. Therefore, Gilead Sciences's EV-to-FCF for today is 17.79.
The historical rank and industry rank for Gilead Sciences's EV-to-FCF or its related term are showing as below:
XTER:GIS'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.99 Med: 12.15 Max: 22.13
Current: 17.36
During the past 13 years, the highest EV-to-FCF of Gilead Sciences was 22.13. The lowest was 5.99. And the median was 12.15.
XTER:GIS's EV-to-FCF is ranked better than 59.61% of 562
companies
in the Drug Manufacturers industry
Industry Median: 21.055
vs XTER:GIS: 17.36
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gilead Sciences's PE Ratio (TTM) for today is calculated as:
Gilead Sciences's share price for today is €114.10.
Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.302.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gilead Sciences EV-to-FCF Related Terms
Gilead Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Gilead Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's EV-to-FCF falls into.
Gilead Sciences's current Enterprise Value is €155,944 Mil.
Gilead Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €8,765 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (XTER:GIS) has a EV-to-FCF of 17.79 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gilead Sciences and its competitors. This is 46% above median its historical median of 12.15. Over the past decade, Gilead Sciences' EV-to-FCF has ranged from 5.99 to 22.13. According to the industry distribution chart, Gilead Sciences ranks #227 out of 562 companies in the Drug Manufacturers industry, placing it in the top 40.4%.
Is Gilead Sciences' EV-to-FCF too high?
Gilead Sciences' current EV-to-FCF of 17.79 is 46% above median its 10-year median of 12.15. Over the past 10 years, this metric has ranged from a low of 5.99 to a high of 22.13. The Drug Manufacturers industry median EV-to-FCF is 21.06. Gilead Sciences' value of 17.79 is 15.5% below this industry median. Based on the distribution chart, Gilead Sciences ranks #227 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gilead Sciences has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' EV-to-FCF compare to PFE and AMGN?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #227 out of 562 companies for EV-to-FCF. This puts Gilead Sciences in the upper half of its industry. The industry median EV-to-FCF is 21.06. Gilead Sciences' value of 17.79 is 15.5% below this benchmark. Historically, Gilead Sciences' own EV-to-FCF has ranged from 5.99 to 22.13 over the past decade. While the company's 10-year median is 12.15 vs. the industry median of 21.06, Gilead Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current EV-to-FCF of 17.79 is 15.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current EV-to-FCF is 17.79, which is 46% above median its own 10-year median of 12.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (XTER:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €83.02, compared to a current price of €114.10 — trading 37.4% above its estimated fair value. The current EV-to-FCF is 17.79, which is 46% above median its 10-year median of 12.15 and 15.5% below the Drug Manufacturers industry median of 21.06. Gilead Sciences' overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Gilead Sciences (XTER:GIS), the current EV-to-FCF is 17.79 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (XTER:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €114.10 is trading 37.4% above its estimated GF Value™ of €83.02.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for XTER:GIS:
EV-to-FCF: 17.79 (46% above median its 10-year median of 12.15)
GF Value™: €83.02 vs. price of €114.10 (37.4% above fair value)
Industry Position: 15.5% below the Drug Manufacturers median (#227 of 562)
No single metric tells the full story. See the XTER:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
82GF Score
Get the complete analysis for XTER:GIS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:GIS has been successfully added to your 
